Slayback Pharma LLC has convinced an administrative tribunal to review two patents related to
The Patent Trial and Appeal Board instituted inter partes review of the patents Wednesday. The board said Slayback “established a reasonable likelihood” the patents’ claims are invalid because they cover inventions that aren’t new or were obvious.
Final validity decisions are expected within 12 months.
Princeton, New Jersey-based Slayback is seeking regulatory approval to sell a generic version of Lumify, a red eye treatment. Slayback asked the PTAB to review U.S. Patent Nos. 9,259,425 and 8,293,742 after it ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.